GlassScriptPhysician profile
Samuel Potolicchio
NPI 1114993367
$4,602.71
in general payments reported to CMS, 2019-2025
40 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $132 · 2021: $502 · 2022: $583 · 2023: $524 · 2024: $750 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $873.02 | 2019-2025 | |
| Abbvie INC. | $511.94 | 2021-2025 | |
| Axsome Therapeutics, INC. | $352.10 | 2022-2025 | Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $330.33 | 2019-2025 | |
| Lilly USA, LLC | $276.48 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Harmony Biosciences LLC | $210.49 | 2024-2025 | |
| Livanova USA, INC. | $185.11 | 2019-2022 | |
| Ucb, INC. | $179.64 | 2024-2025 | Briviact, Nayzilam, Zilbrysq |
| Avadel Cns Pharmaceuticals, LLC | $142.84 | 2024-2025 | Lumryz |
| Biogen, INC. | $109.96 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Celgene Corporation | $106.83 | 2022-2023 | Zeposia |
| Sunovion Pharmaceuticals INC. | $94.38 | 2019-2022 | |
| Eisai INC. | $88.83 | 2019-2025 | |
| Allergan, INC. | $79.18 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $78.81 | 2019-2025 | Ponvory |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Potolicchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.